Several other hedge funds and other institutional investors have also made changes to their positions in NBIX. Rice Hall James & Associates LLC increased its stake in Neurocrine Biosciences by 195.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 206,755 shares of the company’s stock worth $19,383,000 after buying an additional 136,782 shares during the period. HighTower Advisors LLC boosted its stake in Neurocrine Biosciences by 48.8% during the 1st quarter. HighTower Advisors LLC now owns 5,745 shares of the company’s stock valued at $544,000 after purchasing an additional 1,883 shares during the period. PNC Financial Services Group Inc. boosted its stake in Neurocrine Biosciences by 27.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,150 shares of the company’s stock valued at $296,000 after purchasing an additional 684 shares during the period. Acadian Asset Management LLC acquired a new position in Neurocrine Biosciences during the 1st quarter valued at about $27,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Neurocrine Biosciences by 39.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 417,604 shares of the company’s stock worth $39,148,000 after acquiring an additional 117,422 shares during the period. Institutional investors and hedge funds own 92.58% of the company’s stock.
Neurocrine Biosciences Stock Up 0.7 %
NBIX stock opened at $103.54 on Friday. The company has a market capitalization of $10.00 billion, a price-to-earnings ratio of 67.67 and a beta of 0.49. Neurocrine Biosciences, Inc. has a 12 month low of $75.25 and a 12 month high of $129.29. The firm has a 50 day moving average of $112.35 and a two-hundred day moving average of $111.37.
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last posted its earnings results on Monday, February 6th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.15 by $0.09. The company had revenue of $412.00 million during the quarter, compared to the consensus estimate of $408.96 million. Neurocrine Biosciences had a net margin of 10.38% and a return on equity of 10.19%. The company’s revenue for the quarter was up 32.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) earnings per share. On average, research analysts expect that Neurocrine Biosciences, Inc. will post 2.77 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on NBIX. HC Wainwright reaffirmed a “buy” rating and issued a $140.00 price target on shares of Neurocrine Biosciences in a research note on Tuesday, February 7th. BMO Capital Markets boosted their target price on shares of Neurocrine Biosciences from $78.00 to $101.00 in a report on Wednesday, November 2nd. Robert W. Baird boosted their price target on shares of Neurocrine Biosciences from $125.00 to $150.00 in a report on Wednesday, November 2nd. Wedbush boosted their price target on shares of Neurocrine Biosciences from $125.00 to $131.00 and gave the company an “outperform” rating in a report on Tuesday, February 7th. Finally, Mizuho restated a “neutral” rating and set a $116.00 price target on shares of Neurocrine Biosciences in a report on Tuesday, February 7th. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $123.06.
Insiders Place Their Bets
In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,274 shares of the business’s stock in a transaction that occurred on Wednesday, February 8th. The shares were sold at an average price of $104.30, for a total value of $237,178.20. Following the completion of the sale, the chief executive officer now directly owns 491,365 shares of the company’s stock, valued at $51,249,369.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Kevin Charles Gorman sold 2,274 shares of the company’s stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $104.30, for a total transaction of $237,178.20. Following the completion of the sale, the chief executive officer now directly owns 491,365 shares of the company’s stock, valued at approximately $51,249,369.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Matt Abernethy sold 26,328 shares of the company’s stock in a transaction on Tuesday, February 7th. The stock was sold at an average price of $102.40, for a total transaction of $2,695,987.20. Following the sale, the chief financial officer now directly owns 24,333 shares of the company’s stock, valued at $2,491,699.20. The disclosure for this sale can be found here. Insiders sold 119,749 shares of company stock valued at $14,001,823 over the last ninety days. Corporate insiders own 4.40% of the company’s stock.
Neurocrine Biosciences Profile
(Get Rating)
Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm’s product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W.
Featured Stories
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating).
Receive News & Ratings for Neurocrine Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neurocrine Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.